Voluntary announcement Insulin Degludec and Insulin Aspart Injection obtained marketing approval from the china national medical products administration
Filed with HKEX · Stock code 6887 · · 3 pages · English
Summary by 6ix AI
Sunshine Lake Pharma Co., Ltd. has announced that its Insulin Degludec and Insulin Aspart Injection has received marketing approval from the China National Medical Products Administration. With this approval, the company now has seven approved insulin products in the Chinese market, enhancing its product range significantly. The announcement serves to inform investors about the latest developments in the company's business operations.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Sunshine Lake Pharma Co., Ltd. on 6ix
Earlier from Sunshine Lake Pharma
- Next Day Disclosure Return
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
- Interim Report 2026
- Inside information filing with the CSRC in relation to the proposed implementation of h share full circulation
- Lannett Company, Lanexa Biologics and Sunshine Lake Pharma announce FDA Approval of LANGLARA™ an Interchangeable Biosimilar of Lantus® (insulin glargine)
Follow Sunshine Lake Pharma into a list and get an email when it puts out news.
Follow Sunshine Lake Pharma